Core Viewpoint - Ying Tai Medical (01501.HK) has entered into a subscription agreement with Kunbo Medical to acquire a total of 91.09 million shares at a price of HKD 3.11 per share, representing a premium of approximately 1.30% over the closing price on the Hong Kong Stock Exchange [1] Group 1 - The total consideration for the subscription is HKD 283 million, excluding transaction costs, and is subject to the terms and conditions of the subscription agreement [1] - Upon completion, the company will hold approximately 17.24% of Kunbo Medical's issued shares, or about 14.38% of the expanded issued shares post-transaction [1] - Kunbo Medical is an innovative enterprise in the field of interventional pulmonology, focusing on the development of minimally invasive diagnostic and therapeutic products for lung diseases, particularly COPD and lung cancer [1] Group 2 - The subscription is expected to further expand the company's strategic layout in the non-vascular interventional field, given Kunbo Medical's rich product line in this area [2] - The board of directors, including independent non-executive directors, believes that the terms of the subscription agreement are fair and reasonable, established on normal commercial terms, and in the overall interest of the company and its shareholders [2]